GlassScriptPhysician profile
Katelyn S Ponsoll
NPI 1841777190
$6,313.03
in general payments reported to CMS, 2019-2025
40 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $676 · 2022: $1,775 · 2023: $952 · 2024: $1,390 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,829 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.36 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,740.53 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $751.30 | 2021-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $539.63 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $401.69 | 2021-2025 | |
| Amgen INC. | $317.18 | 2022-2025 | Evenity, Tepezza, Repatha |
| Madrigal Pharmaceuticals | $317.05 | 2024-2025 | Rezdiffra |
| Tandem Diabetes Care, INC. | $246.24 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $243.43 | 2021-2025 | Farxiga |
| Medtronic, INC. | $161.83 | 2025 | Minimed 780g |
| Cequr Corporation | $150.03 | 2022-2025 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $121.23 | 2021-2023 | Steglatro |
| Xeris Pharmaceuticals, INC. | $116.39 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $110.76 | 2022-2025 | Korlym |
| Insulet Corporation | $82.34 | 2023-2025 | Omnipod, Omnipod |
| Amarin Pharma, INC. | $79.47 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $77.36 | 2021-2025 | Unithroid |
| Azurity Pharmaceuticals, INC. | $75.55 | 2023-2024 | Triptodur, Triptodur |
| Abbott Laboratories | $67.90 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Horizon Therapeutics Plc | $65.22 | 2022-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $56.17 | 2022-2023 | Isturisa, Signifor Lar |
| Pfizer INC. | $53.01 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $50.33 | 2022 | |
| Kyowa Kirin, INC. | $46.84 | 2024 | Crysvita |
| Exact Sciences Corporation | $46.74 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.52 | 2022-2024 | |
| Eusa Pharma (US) LLC | $42.14 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.50 | 2022-2024 | Jardiance, Synjardy |
| Tolmar, INC. | $24.89 | 2023 | |
| Ascendis Pharma Endocrinology INC | $24.78 | 2024 | |
| Neurocrine Biosciences, INC. | $24.24 | 2025 | |
| Alkermes, INC. | $23.62 | 2025 | Vivitrol |
| Alvogen INC | $23.12 | 2025 | Teriparatide |
| Glaxosmithkline, LLC. | $23.03 | 2023 | Shingrix, Arexvy |
| Sequel Med Tech, LLC | $18.94 | 2025 | Twiist |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.22 | 2025 | Caplyta |
| Antares Pharma, INC. | $18.19 | 2021 | |
| Inspire Medical Systems, INC. | $17.91 | 2025 | Inspire |
| Verona Pharma, INC. | $17.81 | 2025 | Ohtuvayre |
| Janssen Biotech, INC. | $16.49 | 2024 | Tremfya |
| Ibsa Pharma INC. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Ponsoll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.